07.30.13

What Possible Effects Can the Recent United Nations Human Rights Council Resolution Have in Latin American Courts?

By

This post was written by Luis Enrique Rosas (Intern at  Mexican Supreme Court), summer research assistant at Georgetown University Law Center. Any comments or questions about this post can be directed to luisenriquerosas@gmail.com. The 23rd session of The United Nations Human Rights Council was held in Vienna on May 27-June 14, 2013. In the session, […]

Categories:

Tags:

07.22.13

Will FDA Turn the Tide on Industry-wide Medical Product Development?

By

The advent of big data has forced a sea change throughout the scientific research enterprise, shaking the industry’s fundamental attitude towards the data themselves. Data is now understood as the currency of research. Consequently, industry is warming to the new reality that legal norms once considered to drive business – confidential commercial information, trade secrets […]

Categories:

Tags:

07.18.13

Safety and efficacy of electronic cigarettes to quit smoking are not scientifically demonstrated says WHO – A clear answer to a (not so) complicated problem?

By

This post was written by Florian Kastler (Global Health LL.M. 2011), visiting researcher at Georgetown University Law Center. Any comments or questions about this post can be directed to florian.kastler@gmail.com. Last week, on 9 July 2013, the World Health Organization (WHO) updated its Questions and answers on electronic cigarettes or electronic nicotine delivery systems (ENDS) […]

Categories:

Tags:

07.17.13

Industry Trumps Evidence in Tobacco Packaging U-Turn

By

This post was written by Holly Jarman, Research Assistant Professor at the University of Michigan.  For more information about this post, please contact hjarman@umich.edu. The original post can be found at the Huffington Post. The government’s disappointing U-turn over plain packaging of tobacco has dealt a blow to campaigners and shows a government attempting to […]

Categories:

Tags:

07.10.13

Can new FDA graphic warning labels for tobacco pass a first amendment legal challenge?

By

A Georgetown public health expert and attorney examines what the FDA must do to prevail. WASHINGTON — When the U.S. Food and Drug Administration (FDA) imposes new graphic warning labels for tobacco products, they can survive a First Amendment challenge if they depict health consequences and their effectiveness is supported by adequate scientific evidence, says […]

Categories:

Tags:

07.03.13

Recent World Health Organization (WHO) Study Shows Efficacy of Tobacco Control Laws

By

This post was written by Belen Rios, Research Assistant, Global Health LL.M. ‘13, at the O’Neill Institute for National and Global Health Law. Any questions or comments about this post can be directed to mbr55@georgetown.edu. A recent study published by the World Health Organization (WHO) has shown that the adoption of tobacco control laws around the […]

Categories:

Tags:

06.27.13

Nudging one’s way to a healthy lifestyle – A look at regulations in health through the lens of behavioral economics

By

This post was written by Mengyi Xu, O’Neill Institute Summer Intern, Princeton University ’14.  Any comments or questions about this post can be directed to mxu@princeton.edu. To regulate or not to regulate, that is always the question. On the opening day of the O’Neill Institute’s Summer Program on NCDs and law, Professor Alberto Alemanno from HEC […]

Categories:

Tags:

06.25.13

The AMA Recognizes Obesity as a Disease – Why the controversy surrounding this decision is missing the point and why this decision is the good one?

By

This post was written by Florian Kastler (Global Health LL.M. 2011), visiting researcher at Georgetown University Law Center. Any comments or questions about this post can be directed to florian.kastler@gmail.com. By a decision overriding its own council on Science and Public Health, the house of delegates of the American Medical Association (AMA) has officially recognized […]

Categories:

Tags:

06.21.13

The End of “Pay-for-Delay”? By Opening Collusive Pharmaceutical Settlements to Antitrust Scrutiny, FTC v. Actavis Promises to Make Medicines More Affordable

By

  In a decision that could save U.S. consumers and taxpayers billions of dollars a year, the Supreme Court ruled Monday that “pay-for-delay,” also known as “reverse payment” settlements, between name-brand and generics pharmaceutical companies are subject to antitrust laws. The seeds of the controversy were planted in 1984 with the passage of the Hatch-Waxman […]

Categories:

Tags:

06.18.13

2013 Summer Program Day 2!

By

Our 2013 Summer Program on non-communicable diseases (NCDs) is underway! Here’s what our participants have to look forward to on Day 2.

Categories:

Tags:

Stay Informed

Signup for our mailing list and stay up to date on the latest happenings at The O’Neill Institute

Or sign up for our RSS Feed

The views reflected in this blog are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.